Abstract 228P
Background
Recent research has emphasized the pivotal role of tumor-associated macrophages (TAMs) in shaping the efficacy of anti-tumor therapies. Metabolic reprogramming is a key driver of TAM polarization, influencing their pro-tumorigenic or anti-tumorigenic phenotypes. However, the precise mechanisms by which tumor cells manipulate TAM metabolism remain elusive. We have currently discovered that agonistic anti-CD40 antibodies promote anti-tumorigenic TAM activation by enhancing mitochondrial activity and modulating fatty acid oxidation (FAO). We further investigated the interplay between mitochondrial fitness and FAO in regulating TAM immunosuppressive functions.
Methods
We conducted a series of in vitro and in vivo experiments using mouse melanoma tumor models and bone marrow-derived macrophages (BMDMs) for this study.
Results
Our findings demonstrate that lipid-accumulated TAMs exhibit impaired mitochondrial activity, exacerbating their pro-tumorigenic properties. Tumor-derived lipids influence mitochondrial dynamics in TAMs, leading to increased FAO, mitochondrial reactive oxygen species (mtROS) production, and mitophagy. These metabolic alterations collectively contribute to the pro-tumorigenic phenotype of TAMs. Moreover, our research suggests that targeting mitochondrial dynamics-associated pathways may represent a promising therapeutic strategy to reverse TAM immunosuppression and enhance anti-tumor immunity.
Conclusions
This study provides valuable insights into the intricate relationship between lipid metabolism, mitochondrial dynamics, and TAM polarization within the tumor microenvironment (TME). By elucidating how lipid metabolism interacts with mitochondrial dynamics to modulate TAM phenotypes, we aim to develop innovative therapeutic approaches targeting these pathways to improve anti-tumor responses.
Legal entity responsible for the study
The author.
Funding
National Science and Technology Council (MOST 111-2314-B-400-026-MY3).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session